logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Relapsed ovarian cancer: cediranib/olaparib combo extends PFS

Phase 2 data show effect is driven by subset without a known BRCA mutation.